Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial
Zoë Zuilhof, Sandhaya Norris, Claude Blondeau, Pierre Tessier, Pierre Blier Department of Psychiatry, University of Ottawa, The Royal Ottawa Institute of Mental Health Research, Ottawa, ON, Canada Introduction: This study investigated if optimized dose regimens of escitalopram and bupropi...
Guardado en:
Autores principales: | Zuilhof Z, Norris S, Blondeau C, Tessier P, Blier P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9d33968dcc3f457d80e20b1b7ceec6e4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Escitalopram, bupropion, lurasidone, lamotrigine and possible vortioxetine overdose presented with serotonin syndrome and diffuse encephalopathy: A case report
por: Suthimon Thumtecho, et al.
Publicado: (2021) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018) -
Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021) -
Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study
por: Baune BT, et al.
Publicado: (2021)